Syndax Pharmaceuticals, Inc. (SNDX)

Market Cap	2.17B +79.2%
Revenue (ttm)	172.35M +627.8%
Net Income	-285.42M
EPS	-3.29
Shares Out	88.20M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,202,937
Open	24.05
Previous Close	24.29
Day's Range	23.63 - 24.67
52-Week Range	8.58 - 25.59
Beta	0.41
Analysts	Strong Buy
Price Target	38.69 (+57.02%)
Earnings Date	May 4, 2026

About SNDX

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 3, 2016
• Employees: 298
• Stock Exchange: NASDAQ
• Ticker Symbol: SNDX
• Website: https://syndax.com

Financial Performance

In 2025, Syndax Pharmaceuticals's revenue was $172.35 million, an increase of 627.84% compared to the previous year's $23.68 million. Losses were -$285.42 million, -10.46% less than in 2024.

Analyst Summary

According to 13 analysts, the average rating for SNDX stock is "Strong Buy." The 12-month stock price target is $38.69, which is an increase of 57.02% from the latest price.

Price Target

$38.69

(57.02% upside)

Analyst Consensus: Strong Buy